Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for PFIZER

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

 Bills named in this filing 1
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
 Lobbying activity 6
Health Issues

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21.

Taxation/Internal Revenue Code

Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP.

Medicare/Medicaid

Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21.

Trade (domestic/foreign)

Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962.

Budget/Appropriations

Policies impacting post pandemic public health emergency Covid-19 vaccine reimbursement and distribution. Support for immunization access, access to migraine screening. Support for tick-borne disease research and womens health.

Defense

Issues related to pharmaceutical manufacturing and development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem